Compare LAES & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | PRME |
|---|---|---|
| Founded | 2022 | 2019 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.5M | 666.1M |
| IPO Year | 2022 | 2022 |
| Metric | LAES | PRME |
|---|---|---|
| Price | $2.73 | $3.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $4.00 | ★ $7.56 |
| AVG Volume (30 Days) | ★ 12.8M | 1.8M |
| Earning Date | 03-31-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | $93.36 | $7.06 |
| Revenue Next Year | $43.06 | $47.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $1.99 | $1.11 |
| 52 Week High | $8.71 | $6.94 |
| Indicator | LAES | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 50.15 |
| Support Level | $2.54 | $3.17 |
| Resistance Level | $2.88 | $3.94 |
| Average True Range (ATR) | 0.22 | 0.22 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 56.98 | 55.34 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.